Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLEVELAND, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended June 30, 2013. “We are currently evaluating MultiStem® in two Phase II clinical trials, in ulcerative colitis and ischemic stroke, and are now moving a third program into Phase II development,” said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer. “With the recently-awarded SBIR Fast Track grant, we plan to initiate early next year a Phase II trial administrating MultiStem to patients who have suffered an acute myocardial infarction (AMI), building on the promising results demonstrated in our AMI Phase I trial.”
Help employers find you! Check out all the jobs and post your resume.
